BlackRock Fund Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

BlackRock Fund Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$12.9M	Buy	91,757 +15,273	+20%	+$2.06M	﹤0.01%	2432
2016 Q3	$11.2M	Buy	76,484 +5,165	+7%	+$621K	﹤0.01%	2396
2016 Q2	$7.18M	Buy	71,319 +794	+1%	+$103K	﹤0.01%	2602
2016 Q1	$9.44M	Buy	70,525 +1,222	+2%	+$135K	﹤0.01%	2383
2015 Q4	$13.8M	Sell	69,303 -5,058	-7%	-$1.1M	﹤0.01%	2264
2015 Q3	$11.7M	Buy	74,361 +3,386	+5%	+$906K	﹤0.01%	2303
2015 Q2	$29M	Buy	70,975 +13,005	+22%	+$5.62M	0.01%	1883
2015 Q1	$26.6M	Buy	57,970 +6,944	+14%	+$2.99M	0.01%	1914
2014 Q4	$28.6M	Buy	51,026 +29,533	+137%	+$16.8M	0.01%	1846
2014 Q3	$11.3M	Buy	21,493 +1,087	+5%	+$613K	﹤0.01%	2280
2014 Q2	$14.2M	Buy	20,406 +5,669	+38%	+$2.64M	﹤0.01%	2200
2014 Q1	$6.83M	Buy	14,737 +523	+4%	+$265K	﹤0.01%	2626
2013 Q4	$4.89M	Buy	+14,214	New	+$3.93M	﹤0.01%	2840

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Fund Advisors's KPTI Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Karyopharm Therapeutics (KPTI) stake by 20% in Q4 2016, buying an estimated $2.06M and bringing the position to 91,757 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2432.

BlackRock Fund Advisors first reported a position in KPTI in Q4 2013 and has held it in 13 quarters since. The position peaked at $29M in Q2 2015. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

BlackRock Fund Advisors held 91,757 shares of Karyopharm Therapeutics worth $12.9M as of Q4 2016.
BlackRock Fund Advisors bought 15,273 Karyopharm Therapeutics shares in Q4 2016, an estimated $2.06M.
Karyopharm Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2432 holding.
BlackRock Fund Advisors first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 13 quarters since.
BlackRock Fund Advisors's Karyopharm Therapeutics position peaked at $29M in Q2 2015.
86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.